Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 28, 2015 6:11 PM ET


Company Overview of Altor BioScience Corporation

Company Overview

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...

2810 North Commerce Parkway

Miramar, FL 33025-3958

United States

Founded in 2002





Key Executives for Altor BioScience Corporation

Chief Executive Officer, President, and Director
Vice President of Research and Development
Chief Business Officer
Compensation as of Fiscal Year 2014.

Altor BioScience Corporation Key Developments

Altor Bioscience Corporation Appoints Kevin Taylor as Chief Business Officer

Altor BioScience Corporation has appointed Mr. Kevin Taylor as its Chief Business Officer. Mr. Taylor will report directly to Hing C. Wong, Ph.D., Chief Executive Officer of Altor. Mr. Taylor brings over 20 years of experience in corporate and business development to the company. He previously was the Chief Business Officer of Nuron Biotech and held business development leadership roles at Cangene Corporation, Adolor Corporation and Codexis. Earlier in his career he held senior positions at Elan Corporation, AstraZeneca and Zeneca Inc.

Altor Bioscience Corporation Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma

Altor BioScience Corporation announced that it has enrolled patients with relapsed or refractory multiple myeloma (MM) in a clinical trial using its IL-15-based immunostimulatory complex ALT-803. This study is supported by a Small Business Innovation Research (SBIR) Phase II grant recently awarded to Altor by the National Cancer Institute (NCI). The MM trial represents the fourth clinical trial in the United States (U.S.) launched by Altor for the ALT-803 superagonist complex in the fight against cancer. As the second most common blood cancer, MM is a cancer of the plasma cells involved in producing antibodies, causing cancer cells to accumulate in the bone marrow and crowding out normal blood cells from fighting off infection. ALT-803 is considered one of the most promising novel immunotherapeutic agents by NCI for cancer treatment. In preclinical studies, ALT-803 potently activates immune cells to defend against disease, simultaneously mobilizing both the innate and adaptive arms of the immune system to elicit rapid and long-lasting anti-tumor responses. Encouraging preclinical studies of ALT-803 in MM led to the development of the ALT-803 clinical study in patients with relapsed or refractory MM. According to NCI, there will be an estimated 24,050 new cases of MM and 11,090 deaths due to MM in the U.S. in 2014. MM is a disease of the elderly with a median age at diagnosis of 69 years. The number of MM patients is expected to increase over time due to the increasing life expectancy of the normal population. Unfortunately, even with the development of novel therapies recently approved by the U.S. Food and Drug Administration (FDA), MM remains an incurable disease and many patients with the disease will eventually relapse. Therefore, Altor's strategy for ALT-803 is to fulfill the needs of this segment of the market and complement or improve the efficacy of currently available therapies.

Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM

Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Warren Marcus, Scientist and Business Development Associate.

Similar Private Companies By Industry

Company Name Region
Amphivena Therapeutics Inc. United States
Harbin Bioengineering United States
Hoechst Marion Roussel Inc. United States
Edison Pharmaceuticals, Inc. United States
Nexus Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
September 10, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Altor BioScience Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at